Skip to main content
. 2022 Sep 15;10(9):e004389. doi: 10.1136/jitc-2021-004389

Figure 2.

Figure 2

Adjuvant optimization for neoantigen peptide vaccine NeoVAC preparation. (A) Schematic representation of the vaccination schedule for screening adjuvant in subcutaneous HCC model. (B) Tumor growth curves of each group (n=5) treated with neoantigen peptides pulsed with different Toll-like receptor agonists as adjuvant (Pam3cks4, Poly(I:C), Mpla, Flagellin, R848 and CpG-ODN). Results are shown as mean±SEM. (C) The representative immunofluorescence image of CD4+ and CD8+ T-cell infiltration in tumor tissues at each treated group, Scare bars, 100 µm (10×), 40 µm (40×). (D) The histogram of ELISPOT assay showing neoantigen-specific reactivity of splenic T cells against the pool of seven neoantigen peptides. Results are shown as mean±SD. (E) Schematic representation of the vaccination schedule for screening adjuvant in orthotopic HCC model. (F) Tumor burden monitoring of each group (n=5) treated with neoantigen peptides pulsed with different adjuvant by bioluminescence imaging. Neo, neoantigen peptides. The statistical analysis was performed with analysis of variance analysis. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. HCC, hepatocellular carcinoma; IFN, interferon; PBS, phosphate buffered saline.